Screening for Anal Cancer Among Men Who Have Sex With Men With HIV: Benefits, Harms, and Cost-Effectiveness Analyses
Annals of Internal Medicine · 2025
DOI: 10.7326/annals-24-01426 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Internal Medicine, 2025. Verfasst von Ashish A Deshmukh und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health Sciences and Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina (A.A.D., H.D., K.So…. Hauptthemen laut MEDLINE: Anus Neoplasms, Homosexuality, Male, HIV Infections, Papillomavirus Infections. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: World Health Organization, NCI NIH HHS.
Abstract (Originalsprache)
BACKGROUND: Following the success of the ANCHOR (Anal Cancer-HSIL Outcomes Research) trial, the U.S. Department of Health and Human Services recommends anal cancer screening for high-risk persons, particularly men who have sex with men (MSM) with HIV. OBJECTIVE: To quantify the cost-effectiveness and benefits versus harms of different anal cancer screening strategies. DESIGN: Microsimulation model. DATA SOURCES: The ANCHOR trial and published literature. TARGET POPULATION: MSM with HIV. TIME HORIZON: Lifetime. PERSPECTIVE: Health care sector. INTERVENTION: Cytology alone and human papillomavirus (HPV) testing (high-risk HPV [hrHPV], HPV16/18, and HPV16), co-testing, and triage options; ages at which to begin screening (≥35, ≥40, or ≥45 years); screening interval (annual, biennial, triennial, or quadrennial). OUTCOME MEASURES: Incremental cost-effectiveness ratios (ICERs) of dollars per quality-adjusted life-year (QALY) and the tradeoff of harms (high-resolution anoscopies [HRAs]) versus benefits (cancer cases averted and life-years gained). RESULTS OF BASE-CASE ANALYSIS: Screening initiation at age 35 years or older using cytology dominated initiation at ages 40 and 45 years or older, with ICERs ranging from $87 731 for a quadrennial interval to $350 100 for an annual interval. In the comparative analysis, the following unique strategies were on the cost-effectiveness frontier: quadrennial HPV16, quadrennial HPV16/18, triennial HPV16/18, triennial hrHPV, biennial HPV16/18, biennial hrHPV, annual cytology with hrHPV triage, and annual hrHPV; ICERs ranged from $81 341 to $2 510 847. In the harm-to-benefit analysis, triage options offered the most efficient HRA use. RESULTS OF SENSITIVITY ANALYSIS: ICERs decreased for newly eligible persons. For 35-year-old newly eligible MSM with HIV, ICERs for cytology ranged from $70 750 (quadrennial) to $223 895 (annual). LIMITATION: Findings are not generalizable to other high-risk populations. CONCLUSION: Anal cancer screening among MSM with HIV aged 35 years or older is cost-effective, but value-based prioritization of strategies is needed to optimize screening use. PRIMARY FUNDING SOURCE: National Cancer Institute.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Public Health Sciences and Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina (A.A.D., H.D., K.Sonawane).
- Department of General Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, New York (K.Sigel).
- Department of Medicine, University of California, San Francisco, San Francisco, California (J.M.P.).
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland (M.A.C., N.W.).
- Clinical Cancer Center and Center for AIDS Intervention Research, Medical College of Wisconsin, Milwaukee, Wisconsin (A.G.N.).
- University of Puerto Rico Comprehensive Cancer Center, San Juan, Puerto Rico (A.P.O.).
ORCID-Profile: Ashish A Deshmukh, Haluk Damgacioglu, Joel M Palefsky, Nicolas Wentzensen, Elizabeth Y Chiao, Elizabeth Stier, Eric G Meissner, Anna R Giuliano, Gary M Clifford
Förderung
- World Health Organization
- NCI NIH HHS
Zitieren
APA
Deshmukh, A. A., Damgacioglu, H., Sigel, K., Palefsky, J. M., Clarke, M. A., Wentzensen, N., Nyitray, A. G., Ortiz, A. P., Lin, Y. Y., Chiao, E. Y., Stier, E., Jay, N., Gaisa, M., Liu, Y., Meissner, E. G., Lazenby, G., Giuliano, A. R., Goldstone, S. E., Clifford, G. M., …, & Chhatwal, J. (2025). Screening for Anal Cancer Among Men Who Have Sex With Men With HIV: Benefits, Harms, and Cost-Effectiveness Analyses. Annals of Internal Medicine. https://doi.org/10.7326/annals-24-01426
Vancouver
Deshmukh AA, Damgacioglu H, Sigel K, Palefsky JM, Clarke MA, Wentzensen N, et al. Screening for Anal Cancer Among Men Who Have Sex With Men With HIV: Benefits, Harms, and Cost-Effectiveness Analyses. Annals of Internal Medicine. 2025. doi:10.7326/annals-24-01426
BibTeX
@article{Deshmukh2025,
author = {Deshmukh, Ashish A and Damgacioglu, Haluk and Sigel, Keith and Palefsky, Joel M and Clarke, Megan A and Wentzensen, Nicolas and Nyitray, Alan G and Ortiz, Ana Patricia and Lin, Yueh-Yun and Chiao, Elizabeth Y and Stier, Elizabeth and Jay, Naomi and Gaisa, Michael and Liu, Yuxin and Meissner, Eric G and Lazenby, Gweneth and Giuliano, Anna R and Goldstone, Stephen E and Clifford, Gary M and Sonawane, Kalyani and Chhatwal, Jagpreet},
title = {Screening for Anal Cancer Among Men Who Have Sex With Men With HIV: Benefits, Harms, and Cost-Effectiveness Analyses},
journal = {Annals of Internal Medicine},
year = {2025},
doi = {10.7326/annals-24-01426}
}
EUVIMED